HONG KONG - Shanghai, November 10, 2025 – During the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited ("Sino Biopharm") and Shanghai MediTrust Health Technology Group Co., Ltd. ("MediTrust Health") signed a strategic cooperation agreement. The two parties will carry out in-depth cooperation around innovative drugs and commercial insurance, jointly explore a new model of drug-insurance integration, and help more patients access high-quality, affordable medicines at an earlier stage.

Mr. Tse Hsin, Executive Director and Senior Vice President of Sino Biopharm, and Mr. Wang Rundong, President of MediTrust Health, attended the signing ceremony and delivered speeches. Mr. Li Zhigang, Chairman of MediTrust Health, was present as a witness.

Mr. Tse Hsin highlighted that as a leading Chinese innovative pharmaceutical group, Sino Biopharm generates annual revenue of approximately RMB 30 billion, ranks 38th among the Top 50 Global Pharmaceutical Companies, and has a pipeline of over 120 innovative drugs. With evolving demographics and deepening healthcare reforms, commercial health insurance has become a critical channel for innovative drugs to reach the market. This not only eases pressure on public medical insurance funds but also fuels R&D investment, fostering a sustainable industry cycle.

He emphasized MediTrust Health's role as a pivotal platform connecting pharmaceutical companies, insurers, and patients, giving it a unique edge in advancing "drug-insurance integration". The two parties will further explore AI, data collaboration, and innovative payment solutions to set new benchmarks for industry coordination.

Mr. Wang Rundong noted that MediTrust Health remains patient-centric, leveraging AI and data-driven multi-payment infrastructure to streamline the "diagnosis-treatment-payment" journey. "We envision insurance as more than a reimbursement tool—it should be a bridge to better healthcare, ensuring patients facing critical illnesses gain earlier, more affordable access to treatment with greater peace of mind," he said. The partnership aligns with the "Healthy China 2030" strategy, aiming to enhance drug accessibility and build a win-win ecosystem for the pharmaceutical and insurance sectors.